Strides Pharma Science Limited (STAR) - Total Liabilities
Based on the latest financial reports, Strides Pharma Science Limited (STAR) has total liabilities worth Rs37.78 Billion INR (≈ $408.57 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Strides Pharma Science Limited's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Strides Pharma Science Limited - Total Liabilities Trend (2005–2026)
This chart illustrates how Strides Pharma Science Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Strides Pharma Science Limited total assets.
Strides Pharma Science Limited Competitors by Total Liabilities
The table below lists competitors of Strides Pharma Science Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Jiahua Energy Chemical Industry Co Ltd
SHG:600273
|
China | CN¥3.66 Billion |
|
He Bei Cheng De LoLo Co Ltd
SHE:000848
|
China | CN¥1.20 Billion |
|
Ouster, Inc. Common Stock
NASDAQ:OUST
|
USA | $87.78 Million |
|
Jastrzebska Spotka Weglowa SA
WAR:JSW
|
Poland | zł10.75 Billion |
|
Genusplus Group Ltd
AU:GNP
|
Australia | AU$311.19 Million |
|
Gold.com, Inc.
NYSE:GOLD
|
USA | $3.27 Billion |
|
Jiangsu Bide Science and Technology Co. Ltd.
SHG:605298
|
China | CN¥227.94 Million |
|
Exzeo Group, Inc.
NYSE:XZO
|
USA | $104.83 Million |
Liability Composition Analysis (2005–2026)
This chart breaks down Strides Pharma Science Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Strides Pharma Science Limited balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Strides Pharma Science Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Strides Pharma Science Limited (2005–2026)
The table below shows the annual total liabilities of Strides Pharma Science Limited from 2005 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs37.78 Billion ≈ $408.57 Million |
+9.12% |
| 2025-03-31 | Rs34.62 Billion ≈ $374.43 Million |
-8.12% |
| 2024-03-31 | Rs37.68 Billion ≈ $407.50 Million |
-15.62% |
| 2023-03-31 | Rs44.66 Billion ≈ $482.93 Million |
-2.77% |
| 2022-03-31 | Rs45.93 Billion ≈ $496.67 Million |
+9.32% |
| 2021-03-31 | Rs42.01 Billion ≈ $454.32 Million |
+18.10% |
| 2020-03-31 | Rs35.57 Billion ≈ $384.68 Million |
-31.65% |
| 2019-03-31 | Rs52.04 Billion ≈ $562.78 Million |
+32.26% |
| 2018-03-31 | Rs39.35 Billion ≈ $425.51 Million |
-24.95% |
| 2017-03-31 | Rs52.42 Billion ≈ $566.94 Million |
+10.29% |
| 2016-03-31 | Rs47.53 Billion ≈ $514.03 Million |
+259.41% |
| 2015-03-31 | Rs13.22 Billion ≈ $143.02 Million |
+30.10% |
| 2014-03-31 | Rs10.17 Billion ≈ $109.93 Million |
-62.34% |
| 2013-03-31 | Rs26.99 Billion ≈ $291.93 Million |
-33.29% |
| 2012-03-31 | Rs40.46 Billion ≈ $437.59 Million |
+37.72% |
| 2011-03-31 | Rs29.38 Billion ≈ $317.75 Million |
+37.28% |
| 2010-03-31 | Rs21.40 Billion ≈ $231.46 Million |
+23.59% |
| 2009-03-31 | Rs17.32 Billion ≈ $187.28 Million |
-0.47% |
| 2008-03-31 | Rs17.40 Billion ≈ $188.17 Million |
+118.53% |
| 2007-03-31 | Rs7.96 Billion ≈ $86.11 Million |
+35.10% |
| 2006-03-31 | Rs5.89 Billion ≈ $63.74 Million |
+79.15% |
| 2005-03-31 | Rs3.29 Billion ≈ $35.58 Million |
-- |
About Strides Pharma Science Limited
Strides Pharma Science Limited, a pharmaceutical company, engages in the development, manufacturing, and marketing of pharmaceutical products in North America, Australia, Africa, Europe, India, the rest of Asia, and internationally. The company offers generic finished dosage formulations in a range of dosages, such as tablets, hard capsules, sachets, liquids, nasalsprays, topical formulations, an… Read more